Monoclonal Antibodies (-mab), Checkpoint Inhibitors, Kinase Inhibitors (-nib), DMARDs & Immunosuppressants

Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors neutralize the master macrophage cytokine responsible for synovial pannus formation, endothelial adhesion molecule expression, and caseating granuloma maintenance. They are divided structurally into three groups: (1) Monoclonal IgG1 Antibodies against TNF-α: Infliximab (IV chimeric -ximab), Adalimumab (SC fully human -umab), and Golimumab (SC fully human), which bind both soluble and transmembrane TNF-α and lyse TNF-expressing inflammatory cells via complement/ADCC—making them highly effective across Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, AND both Crohn Disease and Ulcerative Colitis; (2) Certolizumab pegol, a PEGylated humanized Fab' fragment lacking an Fc region—because it lacks an Fc domain, certolizumab does NOT undergo FcRn-mediated transplacental transport and is the safest anti-TNF biologic during pregnancy!; and (3) Etanercept, a soluble dimeric fusion protein combining the extracellular ligand-binding portion of the human p75 TNF Receptor-2 (TNFR2) linked to the Fc portion of human IgG1 (binds soluble TNF-α and TNF-β [lymphotoxin] as a decoy receptor; effective in RA, psoriasis, and ankylosing spondylitis, but INEFFECTIVE in Crohn disease / Ulcerative Colitis and granulomatous uveitis!).

High-yield NBOME/USMLE board rules for all TNF-α inhibitors: Because TNF-α secreted by macrophages is strictly required to maintain the integrity of caseating granulomas that wall off dormant mycobacteria and endemic fungi, initiating any TNF-α inhibitor causes granuloma breakdown and disseminated reactivation of latent Mycobacterium tuberculosis (TB), Histoplasmosis, Coccidioidomycosis, and Blastomycosis! Therefore, every patient MUST undergo latent TB screening (Interferon-Gamma Release Assay [QuantiFERON-TB Gold] or Tuberculin Skin Test [PPD] + chest X-ray) AND Hepatitis B screening (HBsAg, anti-HBc) BEFORE starting any anti-TNF agent! Other signature anti-TNF toxicities include Drug-Induced Lupus (anti-dsDNA and anti-histone antibodies), central/peripheral demyelination (strictly contraindicated in Multiple Sclerosis!), worsening NYHA Class III/IV heart failure, and lymphoma/non-melanoma skin cancer.

• Anti-CD20 Monoclonal Antibodies (Rituximab [chimeric], Ocrelizumab [humanized], Ofatumumab [fully human]): Bind the transmembrane phosphoprotein CD20 expressed on pre-B cells and mature naive/memory B lymphocytes (importantly, pro-B cells and terminally differentiated antibody-secreting Plasma Cells do NOT express CD20!). Depletes B cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Approved for CD20+ B-cell Non-Hodgkin Lymphomas (DLBCL, Follicular Lymphoma), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, ANCA-Associated Vasculitis (GPA/MPA), Pemphigus Vulgaris, Warm Autoimmune Hemolytic Anemia, ITP, and Multiple Sclerosis (Ocrelizumab is the ONLY disease-modifying agent approved for Primary Progressive MS!). Signature boxed warnings: (1) Fulminant Hepatitis B Virus (HBV) Reactivation (screen HBsAg and anti-HBc before dosing and give entecavir/tenofovir prophylaxis!); (2) JC Virus Reactivation causing Progressive Multifocal Leukoencephalopathy (PML); and (3) Cytokine-release infusion reactions and hypogammaglobulinemia.

• Abatacept (CTLA-4-Ig Fusion Protein): Naive T-cell activation requires two signals: Signal 1 (MHC-II peptide binding the TCR) and Signal 2 (APC CD80/CD86 [B7] binding T-cell CD28). Abatacept is a soluble fusion protein of the extracellular domain of CTLA-4 linked to IgG1 Fc that binds CD80/86 on antigen-presenting cells with higher affinity than CD28, blocking co-stimulatory Signal 2 in refractory Rheumatoid Arthritis (never combine with TNF inhibitors due to severe infection risk; related derivative Belatacept is used for EBV-seropositive renal transplant maintenance).

• Tocilizumab & Sarilumab (Anti-IL-6 Receptor mAbs): Block soluble and membrane-bound IL-6 receptors, inhibiting hepatocyte acute-phase synthesis (CRP, ESR, amyloid A, hepcidin). First-line steroid-sparing biologic for Giant Cell (Temporal) Arteritis, Systemic Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, and CAR-T-Cell Therapy-Induced Cytokine Release Syndrome (CRS)!

• Belimumab (Anti-BLyS / BAFF mAb) & Anifrolumab (Anti-Type I IFNAR1): Belimumab binds soluble B-Lymphocyte Stimulator (BLyS / BAFF) to inhibit autoreactive B-cell survival in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis.

In the Type 2 (Th2 / ILC2) Allergic and Eosinophilic Inflammation cascade, three classes of monoclonal antibodies target distinct molecular effectors:

1. Dupilumab (also referenced as dupimumab): A fully human monoclonal antibody that binds the alpha subunit of the Interleukin-4 Receptor (IL-4Rα). Because the IL-4Rα chain is shared by both Type I (IL-4) and Type II (IL-4/IL-13) receptor complexes, dupilumab simultaneously blocks signaling of BOTH IL-4 (which drives B-cell IgE class switching and Th2 differentiation) AND IL-13 (which drives goblet cell mucus hypersecretion, airway remodeling, and epidermal filaggrin barrier downregulation)! Dupilumab is a cornerstone biologic for moderate-to-severe Atopic Dermatitis (Eczema), Eosinophilic or Oral-Corticosteroid-Dependent Asthma, Chronic Rhinosinusitis with Nasal Polyps, Eosinophilic Esophagitis (EoE), and Prurigo Nodularis (signature adverse effect: conjunctivitis / blepharitis and transient peripheral blood eosinophilia).

2. Omalizumab (Anti-IgE mAb): A humanized mAb that binds the Cε3 domain of free circulating IgE (the exact region that binds the high-affinity FcεRI receptor on mast cells and basophils). Because omalizumab only binds free IgE and cannot cross-link IgE already bound to mast cell FcεRI, it avoids triggering mast cell degranulation while downregulating surface FcεRI expression in Severe Allergic Asthma, Chronic Spontaneous Urticaria, and IgE-Mediated Food Allergy.

3. Anti-IL-5 Biologics (Mepolizumab, Reslizumab, Benralizumab): Because IL-5 is the primary cytokine governing eosinophil differentiation, maturation, and survival, Mepolizumab and Reslizumab neutralize free IL-5 ligand, whereas Benralizumab binds the IL-5 Receptor alpha (IL-5Rα) on eosinophils and basophils to induce rapid NK-cell ADCC eosinophil depletion in Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss).

4. IL-1 Inhibitors (Anakinra, Canakinumab, Rilonacept): Anakinra is a recombinant human IL-1 Receptor Antagonist (IL-1Ra) and Canakinumab is an anti-IL-1β mAb used for Cryopyrin-Associated Periodic Syndromes (CAPS / NLRP3 inflammasome gain-of-function), Familial Mediterranean Fever, Systemic JIA / Adult-Onset Still Disease, Recurrent Pericarditis, and refractory Acute Gout flares.

• Natalizumab vs. Vedolizumab (Leukocyte Integrin Trafficking Blockade): Leukocyte transendothelial migration requires leukocyte surface integrins to bind endothelial cell adhesion molecules. Natalizumab binds the alpha-4 (α4) integrin subunit of both α4β1 (VLA-4, which binds VCAM-1 on blood-brain barrier endothelium) and α4β7 (which binds MAdCAM-1 on intestinal mucosal endothelium). While highly effective for relapsing-remitting Multiple Sclerosis and Crohn disease, blocking α4β1 prevents CD4+/CD8+ T-cell immune surveillance inside the central nervous system, causing fatal reactivation of latent John Cunningham (JC) polyomavirus and Progressive Multifocal Leukoencephalopathy (PML—asymmetric demyelinating white matter lesions! Always check anti-JC virus antibody index before and during natalizumab therapy!). By contrast, Vedolizumab selectively binds the gut-specific α4β7 integrin heterodimer (blocking interaction with intestinal MAdCAM-1 without touching CNS α4β1/VCAM-1), providing gut-selective immunosuppression for Ulcerative Colitis and Crohn Disease with ZERO risk of JC virus PML!

• Eculizumab & Ravulizumab (Terminal Complement C5 Inhibitors): Humanized monoclonal antibodies that bind complement protein C5, preventing its cleavage into C5a (anaphylatoxin) and C5b (which initiates the C5b-9 Membrane Attack Complex [MAC]). Eculizumab is the gold-standard treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH—acquired PIGA mutation causing loss of GPI-anchored CD55/CD59 on RBCs), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (AChR+), and Neuromyelitis Optica Spectrum Disorder (AQP4+). Crucial boxed warning: Because C5b-9 MAC is essential for serum bactericidal lysis of encapsulated Neisseria species, eculizumab confers a >1,000-fold increased risk of fulminant meningococcemia and meningococcal meningitis—every patient MUST receive both quadrivalent MenACWY AND serogroup B (MenB) meningococcal vaccines at least 2 weeks prior to starting eculizumab (or prophylactic penicillin if urgent therapy is required)!

• Denosumab (Anti-RANKL) & Romosozumab (Anti-Sclerostin): Denosumab mimics endogenous osteoprotegerin (OPG) by binding RANKL (secreted by osteoblasts), preventing RANKL from activating RANK on osteoclast precursors and inhibiting bone resorption in osteoporosis and bone metastases (safe in severe CKD/dialysis unlike bisphosphonates, but causes severe hypocalcemia if vitamin D-deficient, osteonecrosis of the jaw, and rebound vertebral fractures if stopped abruptly!). Romosozumab binds osteocyte-derived sclerostin (an inhibitor of canonical Wnt/beta-catenin signaling), uniquely exerting a dual effect of increasing osteoblastic bone formation AND decreasing osteoclastic bone resorption (boxed warning: increases risk of myocardial infarction and stroke; contraindicated within 1 year of MI/stroke!).

Because CTLA-4 and PD-1/PD-L1 normally maintain peripheral self-tolerance by restraining autoreactive T cells, unleashing these checkpoints triggers autoimmune Immune-Related Adverse Events (irAEs) that can strike virtually any organ system weeks to months after starting therapy (especially severe when combining ipilimumab + nivolumab):

• Endocrinopathies (Often Irreversible!): Ipilimumab (anti-CTLA-4) famously causes Autoimmune Hypophysitis (anterior panhypopituitarism) presenting with severe headache, profound fatigue, hypotension, hyponatremia, and secondary adrenal insufficiency (low cortisol AND low ACTH) plus central hypothyroidism (low free T4 AND low/inappropriately normal TSH) with pituitary stalk thickening on MRI! PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab) more commonly cause Autoimmune Thyroiditis (an initial transient painless hyperthyroid thyrotoxicosis phase followed by permanent primary hypothyroidism) and fulminant Autoimmune Type 1 Diabetes Mellitus presenting in Diabetic Ketoacidosis (DKA).

• GI, Pulmonary, Hepatic, Cutaneous & Cardiac irAEs: Immune-mediated Enterocolitis (profuse watery or bloody diarrhea; rule out C. difficile and CMV), Immune-mediated Pneumonitis (dyspnea, dry cough, ground-glass infiltrates), Autoimmune Hepatitis (AST/ALT transaminitis), maculopapular pruritic rash / vitiligo (vitiligo in melanoma patients actually correlates with favorable anti-tumor response!), and rare but highly lethal Autoimmune Myocarditis / Myasthenia Gravis / Myositis overlap syndrome.

• Board Management Algorithm for irAEs: For Grade 1 (mild) toxicity, continue ICI with symptomatic care; for Grade 2 (moderate), hold the checkpoint inhibitor and initiate oral Prednisone (0.5–1 mg/kg/day); for Grade 3–4 (severe/life-threatening colitis, pneumonitis, hepatitis, or myocarditis), permanently discontinue the checkpoint inhibitor and administer high-dose IV Methylprednisolone (1–2 mg/kg/day)! If severe immune-mediated colitis is refractory to 48–72 hours of high-dose corticosteroids, add Infliximab (or vedolizumab); if autoimmune hepatitis is steroid-refractory, add Mycophenolate mofetil (NEVER give infliximab for immune-mediated hepatitis due to hepatotoxicity!). Notably, for endocrine irAEs (hypothyroidism, adrenal insufficiency), simply replace the missing hormone (hydrocortisone + levothyroxine) and continue immunotherapy once stable!

• Trastuzumab & Pertuzumab (Anti-HER2 / ErbB2 / c-erbB2 mAbs): Trastuzumab binds extracellular subdomain IV of the HER2 receptor tyrosine kinase (overexpressed via ERBB2 gene amplification in ~20% of breast cancers and gastric/GEJ adenocarcinomas), whereas Pertuzumab binds subdomain II to prevent HER2-HER3 heterodimerization. High-yield board toxicity: HER2 signaling is required by adult cardiomyocytes for stress survival; consequently, trastuzumab causes a dose-independent, reversible Type II dilated cardiomyopathy (systolic heart failure / decreased LVEF) that is dramatically worsened by prior or concurrent anthracyclines (doxorubicin)! Always obtain a baseline and serial q3-month echocardiogram (or MUGA scan) during trastuzumab therapy (unlike doxorubicin's irreversible cumulative dose-dependent free-radical myofibrillar necrosis, trastuzumab cardiotoxicity lacks ultrastructural biopsy necrosis and is usually reversible upon holding the drug and starting ACEi/beta-blockers!).

• Bevacizumab & Ramucirumab (Anti-Angiogenesis VEGF/VEGFR2 mAbs): Bevacizumab binds circulating Vascular Endothelial Growth Factor A (VEGF-A) to inhibit tumor neoangiogenesis in metastatic colorectal, renal cell, ovarian, cervical, NSCLC, and glioblastoma multiforme (and is injected intravitreally—alongside ranibizumab and aflibercept—for wet [neovascular] age-related macular degeneration and proliferative diabetic retinopathy). Signature Bevacizumab toxicities: hypertension, nephrotic-range proteinuria / thrombotic microangiopathy, arterial/venous thromboembolism, impaired surgical wound healing (hold ≥28 days before/after major surgery!), life-threatening hemoptysis (contraindicated in squamous cell NSCLC!), and gastrointestinal perforation/fistula.

• Cetuximab & Panitumumab (Anti-EGFR / ErbB1 mAbs): Block the extracellular ligand-binding domain of EGFR in head-and-neck squamous cell carcinoma and metastatic colorectal cancer. Crucial board rule: Anti-EGFR antibodies are ONLY effective in colorectal cancers with WILD-TYPE KRAS, NRAS, and BRAF! If a colorectal tumor harbors a constitutively active downstream KRAS or NRAS mutation, blocking upstream EGFR with cetuximab is 100% futile! (Signature toxicity: papulopustular acneiform facial/truncal rash and renal magnesium wasting / hypomagnesemia).

• Antibody-Drug Conjugates (ADCs) & Bispecific T-Cell Engagers (BiTEs): Brentuximab vedotin links an anti-CD30 mAb (for Hodgkin lymphoma and anaplastic large cell lymphoma) to the microtubule inhibitor MMAE (causes peripheral neuropathy); Trastuzumab deruxtecan (T-DXd) links trastuzumab to a topoisomerase I inhibitor (causes interstitial lung disease); Gemtuzumab ozogamicin targets CD33 in AML (causes sinusoidal obstruction syndrome / veno-occlusive disease); Daratumumab targets CD38 on Multiple Myeloma plasma cells (causes false-positive indirect Coombs antibody screens by binding RBC CD38!); and Blinatumomab is a Bispecific T-Cell Engager (BiTE) that simultaneously binds CD3 on host T cells and CD19 on B-cell Acute Lymphoblastic Leukemia (B-ALL) blasts (boxed warnings: Cytokine Release Syndrome [treated with Tocilizumab] and neurotoxicity/ICANS).

• EGFR Tyrosine Kinase Inhibitors (Osimertinib, Erlotinib, Gefitinib, Afatinib): First-line oral therapy for Non-Small Cell Lung Cancer (NSCLC—typically adenocarcinoma in never-smokers, women, and East Asian patients) harboring activating EGFR exon 19 deletions or exon 21 L858R point mutations. While first-generation erlotinib/gefitinib frequently failed due to acquisition of the secondary EGFR T790M gatekeeper resistance mutation, the third-generation EGFR TKI Osimertinib covalently inhibits both sensitizing EGFR mutations AND the T790M resistance mutation with superior CNS brain-metastasis penetration (toxicities: acneiform rash, secretory diarrhea, and interstitial lung disease / pneumonitis).

• ALK Tyrosine Kinase Inhibitors (Alectinib, Brigatinib, Lorlatinib, Crizotinib): Target the EML4-ALK fusion oncogene (an inversion on chromosome 2 seen in young never-smokers with lung adenocarcinoma). Second-generation Alectinib is preferred first-line over crizotinib due to high CNS penetration.

• BRAF V600E + MEK Inhibitors (Vemurafenib or Dabrafenib or Encorafenib + Trametinib or Cobimetinib): Approximately 50% of cutaneous melanomas (as well as hairy cell leukemia, papillary thyroid cancer, and Langerhans cell histiocytosis) harbor the activating BRAF V600E point mutation (valine-to-glutamate substitution at codon 600), which constitutively phosphorylates downstream MEK1/2 → ERK. Crucial board mechanism: Administering a BRAF inhibitor (vemurafenib or dabrafenib) as monotherapy paradoxically activates CRAF homodimers/heterodimers in normal keratinocytes harboring wild-type BRAF and RAS mutations, causing explosive cutaneous Squamous Cell Carcinomas (SCCs) and keratoacanthomas! Co-administering a downstream MEK1/2 inhibitor (trametinib or cobimetinib) alongside the BRAF inhibitor delays resistance AND reduces the incidence of paradoxical cutaneous squamous cell carcinomas!

• Multi-Kinase Anti-VEGF TKIs (Sunitinib, Sorafenib, Pazopanib, Cabozantinib, Lenvatinib), CDK4/6 Inhibitors (Palbociclib, Ribociclib, Abemaciclib) & PARP Inhibitors (Olaparib, Niraparib, Talazoparib): VEGF TKIs treat clear cell Renal Cell Carcinoma and Hepatocellular Carcinoma (causing hypertension, hand-foot palmar-plantar erythrodysesthesia, and hypothyroidism). CDK4/6 inhibitors (palbociclib) block Retinoblastoma (Rb) protein phosphorylation to arrest the cell cycle at the G1-to-S checkpoint in HR-positive (ER+/PR+), HER2-negative metastatic breast cancer (paired with letrozole or fulvestrant; dose-limiting toxicity: neutropenia). PARP Inhibitors (olaparib) block Poly(ADP-Ribose) Polymerase single-strand DNA break repair; in tumors with homologous recombination deficiency—specifically germline or somatic BRCA1 or BRCA2 mutations (ovarian, breast, pancreatic, and castrate-resistant prostate cancers)—accumulated single-strand breaks collapse replication forks into double-strand breaks that cannot be repaired, killing the tumor cell via synthetic lethality!

• Bruton Tyrosine Kinase (BTK) Inhibitors (Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib): Covalently (or non-covalently for pirtobrutinib) inhibit BTK downstream of the B-cell antigen receptor (BCR) in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, and Waldenström Macroglobulinemia (recall that inherited X-linked loss of BTK causes Bruton agammaglobulinemia!). Two signature board toxicities of ibrutinib are new-onset Atrial Fibrillation and platelet dysfunction / major bleeding (via off-target TEC/collagen glycoprotein VI inhibition).

• BCL-2 Inhibitor (Venetoclax): Follicular lymphoma t(14;18) and CLL overexpress the anti-apoptotic mitochondrial outer membrane protein BCL-2 (which sequesters pro-apoptotic BAX/BAK to prevent cytochrome c release). Venetoclax is a BH3-mimetic small molecule that displaces BAX/BAK from BCL-2, triggering rapid intrinsic mitochondrial apoptosis in CLL and AML. Because venetoclax lyses massive numbers of leukemic cells within hours, its #1 boxed warning is fulminant Tumor Lysis Syndrome (hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, acute kidney injury)—requiring slow 5-week dose ramp-up, aggressive IV hydration, and allopurinol/rasburicase prophylaxis!

• Janus Kinase (JAK) Inhibitors (Tofacitinib, Baricitinib, Upadacitinib, Ruxolitinib): Cytokine receptors lacking intrinsic kinase activity signal via intracellular JAK1, JAK2, JAK3, and TYK2 to phosphorylate STAT transcription factors. Tofacitinib (JAK1/JAK3) and Upadacitinib (selective JAK1) are oral targeted synthetic DMARDs for Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn Disease, and Alopecia Areata, whereas Ruxolitinib (JAK1/JAK2) inhibits constitutively active JAK2 V617F signaling in Polycythemia Vera, Primary Myelofibrosis, and steroid-refractory Graft-versus-Host Disease (GVHD). Crucial FDA boxed warnings for all JAK inhibitors: increased risk of Major Adverse Cardiovascular Events (MACE: MI, stroke), Venous Thromboembolism (DVT/PE), Malignancy, and Herpes Zoster (VZV) reactivation (vaccinate with recombinant Shingrix!).

Sirolimus (Rapamycin) and Everolimus act downstream of IL-2 transcription at Signal 3 (IL-2 receptor signaling). Like tacrolimus, Sirolimus binds the exact same intracellular immunophilin, FKBP12! However, instead of inhibiting calcineurin, the Sirolimus–FKBP12 complex binds and inhibits mTOR (Mechanistic Target of Rapamycin), a serine/threonine kinase downstream of the IL-2 receptor PI3K/Akt pathway. Inhibiting mTOR blocks IL-2-driven phosphorylation of p70S6 kinase and cyclin-dependent kinases, arresting T- and B-lymphocyte proliferation at the G1-to-S phase transition in response to IL-2 (summary: Tacrolimus & Cyclosporine block IL-2 production; Sirolimus & Everolimus block IL-2 response/signaling!).

Why is Sirolimus tested so heavily alongside Tacrolimus and Cyclosporine? Because Sirolimus does NOT cause afferent arteriolar vasoconstriction and is NOT intrinsically nephrotoxic! Therefore, sirolimus or everolimus is the classic board answer when a renal or cardiac transplant recipient develops progressive calcineurin-inhibitor-induced nephrotoxicity and needs a CNI-sparing switch (note also that drug-eluting coronary stents are coated with sirolimus/everolimus to prevent vascular smooth muscle neointimal hyperplasia!). Signature Sirolimus/Everolimus toxicities include: (1) Severe Hypertriglyceridemia / Hyperlipidemia; (2) Bone marrow suppression (thrombocytopenia, leukopenia, anemia); (3) Impaired surgical wound healing / lymphocele formation (avoid immediately post-transplant surgery!); (4) Painful oral aphthous ulcers / mucositis; and (5) Non-infectious interstitial pneumonitis.

To prevent allograft rejection, a CNI (tacrolimus) is paired with an antimetabolite and low-dose prednisone:

• Mycophenolate Mofetil (MMF) & Enteric-Coated Mycophenolate Sodium: Prodrugs rapidly hydrolyzed to mycophenolic acid (MPA), which reversibly and noncompetitively inhibits Inosine Monophosphate Dehydrogenase (IMPDH)—the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides (GMP/GTP/dGTP). Why does inhibiting IMPDH selectively target T and B lymphocytes while sparing most other somatic tissues? Because activated T and B lymphocytes depend 100% on the de novo purine synthesis pathway and lack an effective HGPRT purine salvage pathway, whereas neutrophils, neurons, hepatocytes, and enterocytes can salvage purines via HGPRT! Mycophenolate has largely replaced azathioprine in solid-organ transplantation and is first-line induction/maintenance therapy for Class III/IV/V Lupus Nephritis. Signature Mycophenolate toxicities: (1) Severe gastrointestinal toxicity (watery diarrhea, abdominal cramping, nausea/vomiting); (2) Cytopenias (leukopenia/neutropenia, anemia) and CMV viremia; and (3) Extreme Teratogenicity (FDA Boxed Warning / REMS)—causes first-trimester spontaneous abortion and congenital microtia/ano-otia (absent external ear canals), cleft lip/palate, and conotruncal cardiac defects! In a female lupus nephritis or transplant patient planning pregnancy, STOP Mycophenolate at least 6 weeks before conception and switch to Azathioprine (which is safe in pregnancy because the fetal liver lacks the enzyme inosinate pyrophosphorylase required to convert azathioprine into active 6-mercaptopurine nucleotides!).

• Leflunomide (and active metabolite Teriflunomide): Reversibly inhibits mitochondrial Dihydroorotate Dehydrogenase (DHODH), blocking de novo pyrimidine (UMP/CTP/TMP) synthesis to arrest T-cell proliferation in Rheumatoid Arthritis (leflunomide) and Multiple Sclerosis (teriflunomide). Causes hepatotoxicity, diarrhea, alopecia, hypertension, and extreme teratogenicity (has an enterohepatic circulation half-life of weeks; requires an 11-day oral cholestyramine washout before pregnancy!). Finally, Basiliximab is a chimeric monoclonal antibody that blocks CD25 (the high-affinity alpha-chain of the IL-2 receptor, IL-2Rα) on activated T cells for renal transplant induction without causing bone marrow suppression or nephrotoxicity.

• Hydroxychloroquine (HCQ): An antimalarial weak base that accumulates inside acidic endosomes and lysosomes of antigen-presenting cells, raising intravesicular pH to inhibit MHC Class II autoantigen processing/presentation and endosomal Toll-Like Receptor (TLR7 and TLR9) activation by nucleic acid immune complexes. Hydroxychloroquine is a mandatory cornerstone medication for ALL patients with Systemic Lupus Erythematosus (SLE)—proven to reduce lupus flares, thrombosis, organ damage, and all-cause mortality, and is 100% SAFE to continue throughout Pregnancy (where it also reduces congenital heart block in anti-Ro/SSA-positive mothers!)—and is used for mild Rheumatoid Arthritis (often in 'triple therapy' with methotrexate + sulfasalazine). The #1 board-tested toxicity of chronic hydroxychloroquine (>5 years or dose >5 mg/kg/day) is irreversible Retinal Pigmented Epithelium (RPE) Toxicity ('Bull's-Eye Maculopathy'—paracentral scotomas and central vision loss)—requiring a baseline ophthalmologic exam within the first year and annual spectral-domain OCT + automated visual field screening starting after 5 years of use! (Rarely causes QTc prolongation, neuromyopathy, and G6PD hemolysis).

• Sulfasalazine: An azo-bonded prodrug cleaved by colonic bacterial azoreductases into two active moieties: 5-Aminosalicylic Acid (5-ASA / Mesalamine), which stays in the gut lumen to inhibit colonic epithelial COX/LOX and NF-κB in Ulcerative Colitis, and absorbed Sulfapyridine, which mediates systemic anti-inflammatory activity in Rheumatoid Arthritis (and is safe in pregnancy when paired with folate!). Signature Sulfasalazine toxicities (caused by the sulfapyridine moiety) include reversible Oligospermia / male infertility (sperm count normalizes 2–3 months after stopping!), sulfa hypersensitivity (SJS/DRESS), G6PD hemolytic anemia, folate-deficiency megaloblastic anemia, and Drug-Induced Lupus.

• Apremilast (Oral PDE-4 Inhibitor): Inhibits intracellular Phosphodiesterase-4 (PDE-4) in immune cells, raising intracellular cAMP to activate PKA/CREB, which suppresses TNF-α, IL-17, and IL-23 while increasing anti-inflammatory IL-10 in Psoriatic Arthritis, Plaque Psoriasis, and Behçet Disease oral ulcers (causes weight loss, diarrhea/nausea, and depression, without requiring routine lab monitoring!).

Beyond parenteral monoclonal antibodies (natalizumab, ocrelizumab, alemtuzumab), oral disease-modifying therapies (DMTs) for Relapsing-Remitting Multiple Sclerosis (RRMS) and Ulcerative Colitis target lymphocyte egress and oxidative stress:

• Sphingosine-1-Phosphate (S1P) Receptor Modulators (Fingolimod, Siponimod, Ozanimod, Ponesimod, Etrasimod): Naive and central memory CCR7+ T and B lymphocytes require a gradient of Sphingosine-1-Phosphate (S1P) binding to lymphocyte S1P1 receptors to exit lymph nodes into efferent lymphatics and the bloodstream. Fingolimod and ozanimod act as functional antagonists that bind and internalize/degrade lymphocyte S1P1 receptors—trapping autoreactive lymphocytes inside secondary lymph nodes so they cannot traffic into the CNS (in Multiple Sclerosis) or colonic lamina propria (ozanimod/etrasimod in Ulcerative Colitis)! High-yield Fingolimod board toxicities: Because S1P receptors are also expressed on atrial SA/AV nodal myocytes, retinal capillaries, and bronchial smooth muscle, the first dose of Fingolimod causes acute transient Bradycardia and AV conduction block (requires 6-hour in-clinic ECG monitoring after the first dose!), Macular Edema (requires baseline and 3–4 month dilated eye exam / OCT!), Bronchospasm, VZV reactivation (confirm VZV immunity before starting!), and rare PML.

• Dimethyl Fumarate (and Diroximel Fumarate) & Interferon-Beta-1a/1b / Glatiramer Acetate: Dimethyl fumarate activates the nuclear transcription factor Nrf2 (Nuclear factor erythroid 2-related factor 2) to upregulate antioxidant response genes in RRMS (signature side effects: intense PGD2-mediated facial flushing [relieved by aspirin!], GI distress, and severe lymphopenia that can predispose to PML). Glatiramer acetate is a synthetic random polymer of four amino acids (L-glutamate, L-lysine, L-alanine, L-tyrosine) that acts as a Myelin Basic Protein (MBP) decoy to shift T cells from Th1 to regulatory Th2 cells (safe in pregnancy; causes transient post-injection chest tightness/flushing), while Interferon-beta downregulates MHC-II and inhibits MMP-9 blood-brain barrier breakdown (causes flu-like myalgias/fevers, depression, and transaminitis/leukopenia).